Shares of Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) have been given a consensus rating of “Buy” by the six research firms that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $61.20.
Several research firms recently commented on ASTH. Stifel Nicolaus increased their price objective on Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Truist Financial increased their price objective on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, August 9th. BTIG Research increased their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. Finally, Robert W. Baird increased their target price on Astrana Health from $54.00 to $67.00 and gave the company an “outperform” rating in a report on Thursday, August 15th.
Get Our Latest Stock Report on ASTH
Institutional Inflows and Outflows
Astrana Health Trading Down 1.0 %
NASDAQ ASTH opened at $59.32 on Thursday. Astrana Health has a 12 month low of $28.86 and a 12 month high of $61.51. The stock has a market cap of $3.32 billion, a P/E ratio of 44.94, a P/E/G ratio of 2.15 and a beta of 1.21. The stock’s fifty day moving average price is $51.26 and its 200-day moving average price is $44.72. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.62.
Astrana Health (NASDAQ:ASTH – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.01. Astrana Health had a return on equity of 10.71% and a net margin of 4.30%. The firm had revenue of $486.30 million for the quarter, compared to analysts’ expectations of $440.68 million. During the same period in the prior year, the firm posted $0.28 earnings per share. The company’s quarterly revenue was up 39.7% on a year-over-year basis. As a group, equities analysts forecast that Astrana Health will post 1.33 EPS for the current fiscal year.
Astrana Health Company Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Recommended Stories
- Five stocks we like better than Astrana Health
- Why Are These Companies Considered Blue Chips?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- High Dividend REITs: Are They an Ideal Way to Diversify?
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.